Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: Phase 2 randomized trial results

Journal of Lipid Research

Volumn 57, Issue 4, 2016, Pages 706-713

  Yang, Xiaohong ^a   Lee, Sang Rok ^a,b   Choi, Yun Seok ^a,c   Alexander, Veronica J ^d   Digenio, Andres ^e   Yang, Qingqing ^d   Miller, Yury I ^a   Witztum, Joseph L ^a   Tsimikas, Sotirios ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Chonbuk National University Medical School and Hospital   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d ISIS PHARMACEUTICALS   (United States)

^e Akcea Therapeutics   (United States)

Author keywords

Antisense oligonucleotides; Apolipoprotein C III; Cardiovascular disease; Familial chylomicronemia syndrome; Hypertriglyceridemia; Remnant lipoproteins; Triglycerides

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; APOLIPOPROTEIN C3; CHYLOMICRON; FIBRIC ACID DERIVATIVE; LIPOPROTEIN A; PLACEBO; VERY LOW DENSITY LIPOPROTEIN; VOLANESORSEN; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; TRIACYLGLYCEROL;

ADD ON THERAPY; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHEMOLUMINESCENCE; COMPLEX FORMATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 1; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; BLOOD; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; GENETICS; METABOLISM; MIDDLE AGED;

APOLIPOPROTEIN C-III; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; TRIGLYCERIDES;

EID: 84963836241     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M066399     Document Type: Article

References (36)

1. Norata, G. D., S. Tsimikas, A. Pirillo, and A. L. Catapano. 2015. Apolipoprotein C-III: from pathophysiology to pharmacology. Trends Pharmacol. Sci. 36:675-687.
2. Huff, M. W., and R. A. Hegele. 2013. Apolipoprotein C-III: going back to the future for a lipid drug target. Circ. Res. 112:1405-1408.
3. Mendivil, C. O., E. B. Rimm, J. Furtado, S. E. Chiuve, and F. M. Sacks. 2011. Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart disease. Circulation. 124:2065-2072.
4. Jensen, M. K., E. B. Rimm, J. D. Furtado, and F. M. Sacks. 2012. Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease. J. Am. Heart Assoc. 1:e000232.
5. Wyler Von Ballmoos, M. C., B. Haring, and F. M. Sacks. 2015. The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis. J. Clin. Lipidol. 9:498-510.
6. Graham, M. J., R. G. Lee, T. A. Bell 3rd, W. Fu, A. E. Mullick, V. J. Alexander, W. Singleton, N. Viney, R. Geary, J. Su, et al. 2013. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112:1479-1490.
7. Gaudet, D., D. Brisson, K. Tremblay, V. J. Alexander, W. Singleton, S. G. Hughes, R. S. Geary, B. F. Baker, M. J. Graham, R. M. Crooke, et al. 2014. Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 371:2200-2206.
8. Gaudet, D., V. J. Alexander, B. F. Baker, D. Brisson, K. Tremblay, W. Singleton, R. S. Geary, S. G. Hughes, N. J. Viney, M. J. Graham, et al. 2015. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N. Engl. J. Med. 373:438-447.
9. Tsimikas, S., H. K. Lau, K. R. Han, B. Shortal, E. R. Miller, A. Segev, L. K. Curtiss, J. L. Witztum, and B. H. Strauss. 2004. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein (a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation. 109:3164-3170.
10. Young, S. G., J. L. Witztum, D. C. Casal, L. K. Curtiss, and S. Bernstein. 1986. Conservation of the low density lipoprotein receptorbinding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis. 6:178-188.
11. Sacks, F. M. 2015. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr. Opin. Lipidol. 26:56-63.
12. Crosby, J., G. M. Peloso, P. L. Auer, D. R. Crosslin, N. O. Stitziel, L. A. Lange, Y. Lu, Z. Z. Tang, H. Zhang, G. Hindy, et al.; TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. 2014. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N. Engl. J. Med. 371:22-31.
13. Jørgensen, A. B., R. Frikke-Schmidt, B. G. Nordestgaard, and A. Tybjaerg-Hansen. 2014. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N. Engl. J. Med. 37:32-41.
14. Schonfeld, G., P. K. George, J. Miller, P. Reilly, and J. Witztum. 1979. Apolipoprotein C-II and C-III levels in hyperlipoproteinemia. Metabolism. 28:1001-1010.
15. Chan, D. C., G. F. Watts, E. M. Ooi, J. Ji, A. G. Johnson, and P. H. Barrett. 2008. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28:1831-1837.
16. Dallinga-Thie, G. M., I. I. Berk-Planken, A. H. Bootsma, and H. Jansen; Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. 2004. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care. 27:1358-1364.
17. Kastelein, J. J., K. C. Maki, A. Susekov, M. Ezhov, B. G. Nordestgaard, B. N. Machielse, D. Kling, and M. H. Davidson. 2014. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the Epanova for Lowering Very High Triglycerides (EVOLVE) trial. J. Clin. Lipidol. 8:94-106.
18. Davidson, M. H., J. Johnson, M. W. Rooney, M. L. Kyle, and D. F. Kling. 2012. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova (®) compared to Lovaza (®) in a pharmacokinetic single-dose evaluation) study. J. Clin. Lipidol. 6:573-584.
19. Qamar, A., S. A. Khetarpal, A. V. Khera, A. Qasim, D. J. Rader, and M. P. Reilly. 2015. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler. Thromb. Vasc. Biol. 35:1880-1888.
20. Maki, K. C., H. E. Bays, M. R. Dicklin, S. L. Johnson, and M. Shabbout. 2011. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia. J. Clin. Lipidol. 5:483-492.
21. Swahn, E., H. Von Schenck, and A. G. Olsson. 1998. Omega-3 ethyl ester concentrate decreases total apolipoprotein CIII and increases antithrombin III in postmyocardial infarction patients. Clin. Drug Investig. 15:473-482.
22. Schuster, H., B. Fagerberg, S. Edwards, T. Halmos, J. Lopatynski, S. Stender, G. S. Birketvedt, S. Tonstad, I. Gause-Nilsson, S. Halldorsdottir, et al. 2008. Tesaglitazar, a dual peroxisome proliferatoractivated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Atherosclerosis. 197:355-362.
23. Fagerberg, B., S. Edwards, T. Halmos, J. Lopatynski, H. Schuster, S. Stender, G. Stoa-Birketvedt, S. Tonstad, S. Halldorsdottir, and I. Gause-Nilsson. 2005. Tesaglitazar, a novel dual peroxisome proliferatoractivated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. Diabetologia. 48:1716-1725.
24. Nagashima, K., C. Lopez, D. Donovan, C. Ngai, N. Fontanez, A. Bensadoun, J. Fruchart-Najib, S. Holleran, J. S. Cohn, R. Ramakrishnan, et al. 2005. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Clin. Invest. 115:1323-1332.
25. Brahm, A. J., and R. A. Hegele. 2015. Chylomicronaemia-current diagnosis and future therapies. Nat. Rev. Endocrinol. 11:352-362.
26. Willeit, P., S. Kiechl, F. Kronenberg, J. L. Witztum, P. Santer, M. Mayr, Q. Xu, A. Mayr, J. Willeit, and S. Tsimikas. 2014. Discrimination and net reclassification of cardiovascular risk with lipoprotein (a): prospective 15-year outcomes in the Bruneck study. J. Am. Coll. Cardiol. 64:851-860.
27. Kronenberg, F., and G. Utermann. 2013. Lipoprotein (a): resurrected by genetics. J. Intern. Med. 273:6-30.
28. Capoulade, R., K. L. Chan, C. Yeang, P. Mathieu, Y. Bosse, J. G. Dumesnil, J. W. Tam, K. K. Teo, A. Mahmut, X. Yang, et al. 2015. Oxidized phospholipids, lipoprotein (a), and progression of calcific aortic valve stenosis. J. Am. Coll. Cardiol. 66:1236-1246.
29. Bouchareb, R., A. Mahmut, M. J. Nsaibia, M. C. Boulanger, A. Dahou, J. L. Lepine, M. H. Laflamme, F. Hadji, C. Couture, S. Trahan, et al. 2015. Autotaxin derived from lipoprotein (a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation. 132:677-690.
30. Kamstrup, P. R., A. Tybjaerg-Hansen, and B. G. Nordestgaard. 2014. Elevated lipoprotein (a) and risk of aortic valve stenosis in the general population. J. Am. Coll. Cardiol. 63:470-477.
31. Thanassoulis, G., C. Y. Campbell, D. S. Owens, J. G. Smith, A. V. Smith, G. M. Peloso, K. F. Kerr, S. Pechlivanis, M. J. Budoff, T. B. Harris, et al. 2013. Genetic associations with valvular calcification and aortic stenosis. N. Engl. J. Med. 368:503-512.
32. Byun, Y. S., J. H. Lee, B. J. Arsenault, X. Yang, W. Bao, D. DeMicco, R. Laskey, J. L. Witztum, S. Tsimikas, and T. N. T. T. Investigators. 2015. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J. Am. Coll. Cardiol. 65:1286-1295.
33. Tsimikas, S., G. W. Duff, P. B. Berger, J. Rogus, K. Huttner, P. Clopton, E. Brilakis, K. S. Kornman, and J. L. Witztum. 2014. Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein (a). J. Am. Coll. Cardiol. 63:1724-1734.
34. Tsimikas, S., P. Willeit, J. Willeit, P. Santer, M. Mayr, Q. Xu, A. Mayr, J. L. Witztum, and S. Kiechl. 2012. Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J. Am. Coll. Cardiol. 60:2218-2229.
35. Scipione, C. A., S. E. Sayegh, R. Romagnuolo, S. Tsimikas, S. M. Marcovina, M. B. Boffa, and M. L. Koschinsky. 2015. Mechanistic insights into lipoprotein (a)-induced interleukin-8 expression: a role for oxidized phospholipid modification of apolipoprotein (a). J. Lipid Res. 56:2273-2285.
36. Tsimikas, S., N. J. Viney, S. G. Hughes, W. Singleton, M. J. Graham, B. F. Baker, J. L. Burkey, Q. Yang, S. M. Marcovina, R. S. Geary, et al. 2015. Antisense therapy targeting apolipoprotein (a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 386:1472-1483.